Home » Market News » DirectorsTalk Highlights » Advanced Oncotherapy Director “buys” more shares in the company
Advanced Oncotherapy Plc

Advanced Oncotherapy Director “buys” more shares in the company

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, has told DirectorsTalk that it was informed on Friday 8 July 2016 that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, on Friday 8 July 2016 purchased 10,000 ordinary shares of 25 pence each in the Company (“Ordinary Shares”) at 119.50 pence per Ordinary Share.

 

Following this transaction, Michael Bradfield now holds 5,050,740 Ordinary Shares representing 8.90% of the issued share capital of the Company.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.